Chemoinformaics analysis of CEDR-8(15)-EN-9-ALPHA-OL
| Molecular Weight | 220.356 | nRot | 0 |
| Heavy Atom Molecular Weight | 196.164 | nRig | 14 |
| Exact Molecular Weight | 220.183 | nRing | 3 |
| Solubility: LogS | -4 | nHRing | 0 |
| Solubility: LogP | 3.38 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 3 |
| Atoms Count | 40 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 16 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 3 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 41.855 |
| nHD | 1 | BPOL | 24.077 |
| QED | 0.62 |
| Synth | 5.775 |
| Natural Product Likeliness | 3.169 |
| NR-PPAR-gamma | 0.006 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0.004 |
| HIA | 0.006 |
| CACO-2 | -4.678 |
| MDCK | 0.0000274 |
| BBB | 0.932 |
| PPB | 0.579943 |
| VDSS | 1.474 |
| FU | 0.348644 |
| CYP1A2-inh | 0.054 |
| CYP1A2-sub | 0.307 |
| CYP2c19-inh | 0.053 |
| CYP2c19-sub | 0.841 |
| CYP2c9-inh | 0.118 |
| CYP2c9-sub | 0.462 |
| CYP2d6-inh | 0.013 |
| CYP2d6-sub | 0.589 |
| CYP3a4-inh | 0.039 |
| CYP3a4-sub | 0.213 |
| CL | 9.161 |
| T12 | 0.04 |
| hERG | 0.007 |
| Ames | 0.005 |
| ROA | 0.324 |
| SkinSen | 0.031 |
| Carcinogencity | 0.043 |
| EI | 0.814 |
| Respiratory | 0.95 |
| NR-Aromatase | 0.012 |
| Antiviral | Yes |
| Prediction | 0.856043 |